Afficher la couverture 'Long-term microdystrophin gene therapy is effective in a canine model of Duchenne muscular dystrophy | Le Guiner, Caroline, C.' en grand format
/5

0 avis

Long-term microdystrophin gene therapy is effective in a canine model of Duchenne muscular dystrophy

Archive ouverte

Le Guiner, Caroline, C. | Servais, Laurent | Montus, Marie | Thibaut, Thibaut | Fraysse, Bodvael | Moullec, Sophie | Allais, Marine | François, Virginie | Dutilleul, Maeva | Malerba, Alberto | Koo, Taeyoung | Thibaut, Jean-Laurent | Matot, Béatrice | Devaux, Marie | Le Duff, Johanne | Deschamps, Jack-Yves | Barthélémy, Inès | Blot, Stéphane | Testault, Isabelle | Wahbi, Karim | Ederhy, Stéphane | Martin, Samia | Veron, Philippe | Georger, Christophe | Athanasopoulos, Takis | Masurier, Carole | Mingozzi, Federico | Carlier, Pierre | Gjata, Bernard | Hogrel, Jean-Yves | Adjali, Oumeya | Mavilio, Fulvio | Voit, Thomas | Moullier, Philippe | Larcher, Thibaut | Thibaut, Laurent | Dickson, George

Edité par CCSD ; Nature Publishing Group -

International audience. Duchenne muscular dystrophy (DMD) is an incurable X-linked muscle-wasting disease caused by mutations in the dystrophin gene. Gene therapy using highly functional microdystrophin genes and recombinant adeno-associated virus (rAAV) vectors is an attractive strategy to treat DMD. Here we show that locoregional and systemic delivery of a rAAV2/8 vector expressing a canine microdystrophin (cMD1) is effective in restoring dystrophin expression and stabilizing clinical symptoms in studies performed on a total of 12 treated golden retriever muscular dystrophy (GRMD) dogs. Locoregional delivery induces high levels of microdystrophin expression in limb musculature and significant amelioration of histological and functional parameters. Systemic intravenous administration without immunosuppression results in significant and sustained levels of microdystrophin in skeletal muscles and reduces dystrophic symptoms for over 2 years. No toxicity or adverse immune consequences of vector administration are observed. These studies indicate safety and efficacy of systemic rAAV-cMD1 delivery in a large animal model of DMD, and pave the way towards clinical trials of rAAV-microdystrophin gene therapy in DMD patients.

Suggestions

Du même auteur

Adeno-Associated Virus Vector (AAV) microdystrophin gene therapy prolongs survival and restores muscle function in the canine model of Duchenne Muscular Dystrophy (DMD)

Archive ouverte | Le Guiner, Caroline | CCSD

Duchenne Muscular Dystrophy (DMD) is a X-linked inherited muscle-wasting disease primarily affecting young boys with a prevalence of 1:5,000. The disease is caused by loss-of-function mutations in the gene encoding for the Dystrop...

Forelimb Treatment in a Large Cohort of Dystrophic Dogs Supports Delivery of a Recombinant AAV for Exon Skipping in Duchenne Patients

Archive ouverte | Le Guiner, Caroline | CCSD

International audience. Duchenne muscular dystrophy (DMD) is a severe muscle-wasting disorder caused by mutations in the dystrophin gene, without curative treatment yet available. Our study provides, for the first t...

an exon skipping strategy using AAV8-U7snRNA vectors for the treatment of Duchenne muscular dystrophy - results in GRMD dogs and clinical perspectives.

Archive ouverte | Le Guiner, Caroline, C. | CCSD

Chargement des enrichissements...